|Mr. Jeffrey W. Renwick||Co-Founder, CEO & Director||20k||N/A||1968|
|Mr. Richard C. Goldstein||Co-Founder, CFO & Director||20k||N/A||1961|
|Mr. Barry M. Polisuk||Chairman & Corp. Sec.||N/A||N/A||1960|
|Mr. Robert Lefler||Director of Operations||N/A||N/A||N/A|
|Mr. Joshi Laxminarayan||Chief Scientific Officer||N/A||N/A||N/A|
Canntab Therapeutics Limited researches and develops advanced pharmaceutical grade formulations of cannabinoids and terpenes in Canada. It offers sustained release, immediate release, modified release, flash melt, and bi-layered tablets for treating sleep disorders, posttraumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.
Canntab Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.